Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats.[2][4] Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.[5] It is taken by mouth.[2]
 | |
| Clinical data | |
|---|---|
| Trade names | Senvelgo |
| License data | |
| Routes of administration | By mouth |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H25NO5 |
| Molar mass | 395.455 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Medical uses
editVelagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin.[2][4][5]
References
edit- ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]". Health Canada. 18 October 2024. Retrieved 25 October 2024.
- ^ a b c d "Senvelgo- velagliflozin solution". DailyMed. 8 November 2023. Retrieved 13 December 2023.
- ^ "Senvelgo Product information". Union Register of veterinary medicinal products. 22 November 2023. Retrieved 29 August 2024.
- ^ a b https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14320
This article incorporates text from this source, which is in the public domain.
- ^ a b "Dear Veterinarian Letter regarding important safety conditions associated with the use of Senvelgo (velagliflozin oral solution) for improving glycemic control in certain cats with diabetes mellitus". U.S. Food and Drug Administration. 4 December 2023. Retrieved 13 December 2023. This article incorporates text from this source, which is in the public domain.
 | This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it. |